BJCM
Blue Jay Capital Management Portfolio holdings
AUM
$147M
1-Year Return
64.18%
This Quarter Return
+11.67%
1 Year Return
+64.18%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$147M
AUM Growth
-$56.7M
(-28%)
Cap. Flow
-$64.4M
Cap. Flow
% of AUM
-43.88%
Top 10 Holdings %
Top 10 Hldgs %
58.43%
Holding
30
New
9
Increased
3
Reduced
8
Closed
10
Top Buys
| 1 |
Qiagen
QGEN
|
+$7.31M |
| 2 |
Smith & Nephew
SNN
|
+$6.97M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$6.74M |
| 4 |
Neurocrine Biosciences
NBIX
|
+$6.68M |
| 5 |
Brookdale Senior Living
BKD
|
+$6.62M |
Top Sells
| 1 |
Biogen
BIIB
|
+$12.7M |
| 2 |
Globus Medical
GMED
|
+$11.8M |
| 3 |
QGENF
QIAGEN NV
QGENF
|
+$11.3M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$10.9M |
| 5 |
BCR
CR Bard Inc.
BCR
|
+$9.3M |
Sector Composition
| 1 | Healthcare | 89.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
DERM
26
DELISTED
Dermira, Inc.
DERM
| – | – |
-210,000
| Closed | -$7.16M |
|
|
CELG
27
DELISTED
Celgene Corp
CELG
| – | – |
-72,902
| Closed | -$9.07M |
|
|
BCR
28
DELISTED
CR Bard Inc.
BCR
| – | – |
-37,419
| Closed | -$9.3M |
|
|
QGENF
29
DELISTED
QIAGEN NV
QGENF
| – | – |
-390,000
| Closed | -$11.3M |
|
|
30
Bristol-Myers Squibb
BMY
$94B
| – | – |
-200,000
| Closed | -$10.9M |
|